Please login to the form below
cell therapies
This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.
Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts
Kite was sold on to Gilead Sciences, along with FDA-approved CAR-T therapy Yescarta, one of the first two of the groundbreaking cell therapies to reach the market, just behind ... allogeneic cell therapy and the potential for greater and faster patient
Latest news
-
Novartis cuts manufacturing jobs in Switzerland and UK
This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as ... The company says it has already invested more than $1bn in
-
CHMP backs Spark’s Luxturna, but rejects Sarepta again
Once approved, Luxturna will be sold in Europe by Novartis, which has been steadily building a portfolio of cell and gene therapies in the last couple of years through licensing deals. ... therapies. The CHMP turned down Sarepta’s application for
-
Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question
in second or later relapse, and also for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ... Novartis says the roll-out of Kymriah in Europe will vary from country to country as it develops an “infrastructure for delivering CAR
-
Armoured CAR ‘could overwhelm solid tumour resistance’
These data, together with in vivo models, suggest that this is an early step toward exploring how we can make the first iterations of CAR-T-cell therapies even better, ”said ... Eureka and Memorial Sloan Kettering have been working together on T-cell
-
Regeneron and Bluebird sign $100m cell therapies deal
Regeneron and Bluebird sign $100m cell therapies deal. Six targets chosen from TCR and other cell therapy platforms. ... Big biotech’Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater
More from news
Approximately 2 fully matching, plus 93 partially matching documents found.
Latest Intelligence
-
Making Europe a leader in bioscience: boosting trust and opening minds
New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and ... This involves incorporating new diagnostic
-
Cancer immunotherapy: What's on the horizon?
Between November 2016 and October 2017, the FDA approved 31 new therapies for more than 16 types of tumour, including the first cell-based therapies, the first tumour-agnostic drugs and ... cell-based therapies and oncolytic viruses that attack malignant
-
Bluebird Bio: on the cusp of a gene therapy revolution
class gene or cell therapies by 2022. ... Cell and gene therapies undoubtedly do pose difficult questions – but there is also no question of holding back because of this business model uncertainty.
-
No incentive for a cure
Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... Healthcare systems are currently set up to cover moderate costs for chronic therapies over a medium to longer period
-
The good, the bad and the ugly
The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
-
Industry appointments
Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand
-
Abeona Therapeutics appoints new additions to board of directors
Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the appointment of Stefano Buono and Richard Van Duyne. ... He said: “Abeona’s ambitious gene
-
Turnstone Biologics bolsters leadership team
Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... Prior to Novartis Perry was global head of R&D for the bioscience division at Baxter Healthcare, vice president of
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... society. “ We look at the manufacturing challenges we are facing for emerging healthcare products, such as
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Meet the CEO behind ReNeuron’ s cutting-edge stem cell therapies. Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’ s latest innovation in ... The biotech creates ‘ off-the-shelf’ cell-based therapies,
-
Introduction to the manufacturing of biologics
However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins ... include blood or blood products, gene therapies, vaccines, and cell
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
The second wave of agents encompasses checkpoint inhibitors and cell therapies, among others.
-
Life at the end of the Brexit tunnel
This investment will cover 5 major projects supporting advanced therapies:. A Medicines Manufacturing Innovation Centre to accelerate the adoption of emerging and novel manufacturing technologies. ... An Advanced Therapies Treatment Centre to develop
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
-
Associate Medical Director
-
Salary TBC
-
Associate Medical Director
-
Highly Competitive
- Director Healthcare PR Communications
-
Salary TBC
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Experienced Editor, London, Medical Communications
-
Competitive package
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Account Manager, Healthcare Advertising
-
Salary TBC
- Account Director – Global Healthcare PR
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Scientific Team Lead
-
Competitive Salary
-
Account Director
-
Negotiable
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
Subscribe to our email news alerts
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
Quick links
Infographics
